TY - JOUR
T1 - Comparative performance data for multiplex SARS-CoV-2 serological assays from a large panel of dried blood spot specimens
AU - Cholette, François
AU - Fabia, Rissa
AU - Harris, Angela
AU - Ellis, Hannah
AU - Cachero, Karla
AU - Schroeder, Lukas
AU - Mesa, Christine
AU - Lacap, Philip
AU - Arnold, Corey
AU - Galipeau, Yannick
AU - Langlois, Marc-André
AU - Colwill, Karen
AU - Gingras, Anne-Claude
AU - McGeer, Allison
AU - Giles, Elizabeth
AU - Day, Jacqueline
AU - Osiowy, Carla
AU - Durocher, Yves
AU - Hankins, Catherine
AU - the COVID-19 Immunity Task Force (CITF) working group
AU - Mazer, Bruce
AU - Drebot, Michael
AU - Kim, John
N1 - Funding Information: We thank David Taylor, Timothy Evans, Heather Hannah, Mona Nemer, Howard Njoo, Gina Olgilvie, Jutta Preiksaitis, Gail Tomblin Murphy, Paul Van Caeseele, Theresa Tam, Stephen Lucas, Vivek Goel, Philippe Gros, Scott Halperin, Charu Kauschic, James D. Kellner, Susan Kirkland, Gary Kobinger, Mel Krajden, Christie Lutsiak, Richard Massé, Deborah Money, Caroline Quach-Thanh, and Rosann Seviour of the CITF Leadership Group for their support. We also thank Bhavisha Rathod and members of the Network Biology Collaborative Centre (nbcc.lunenfeld.ca; a facility supported by the Canada Foundation for Innovation, the Ontario Government, and Genome Canada and Ontario Genomics [ OGI-139 ]) for the assays using the Mount Sinai Hospital protocol. Publisher Copyright: © 2022
PY - 2022/9
Y1 - 2022/9
N2 - The extent of the COVID-19 pandemic will be better understood through serosurveys and SARS-CoV-2 antibody testing. Dried blood spot (DBS) samples will play a central role in large scale serosurveillance by simplifying biological specimen collection and transportation, especially in Canada. Direct comparative performance data on multiplex SARS-CoV-2 assays resulting from identical DBS samples are currently lacking. In our study, we aimed to provide performance data for the BioPlex 2200 SARS-CoV-2 IgG (Bio-Rad), V-PLEX SARS-CoV-2 Panel 2 IgG (MSD), and Elecsys Anti-SARS-CoV-2 (Roche) commercial assays, as well as for two highly scalable in-house assays (University of Ottawa and Mount Sinai Hospital protocols) to assess their suitability for DBS-based SARS-CoV-2 DBS serosurveillance. These assays were evaluated against identical panels of DBS samples collected from convalescent COVID-19 patients (n = 97) and individuals undergoing routine sexually transmitted and bloodborne infection (STBBI) testing prior to the COVID-19 pandemic (n = 90). Our findings suggest that several assays are suitable for serosurveillance (sensitivity >97% and specificity >98%). In contrast to other reports, we did not observe an improvement in performance using multiple antigen consensus-based rules to establish overall seropositivity. This may be due to our DBS panel which consisted of samples collected from convalescent COVID-19 patients with significant anti-spike, -receptor binding domain (RBD), and -nucleocapsid antibody titers. This study demonstrates that biological specimens collected as DBS coupled with one of several readily available assays are useful for large-scale COVID-19 serosurveillance.
AB - The extent of the COVID-19 pandemic will be better understood through serosurveys and SARS-CoV-2 antibody testing. Dried blood spot (DBS) samples will play a central role in large scale serosurveillance by simplifying biological specimen collection and transportation, especially in Canada. Direct comparative performance data on multiplex SARS-CoV-2 assays resulting from identical DBS samples are currently lacking. In our study, we aimed to provide performance data for the BioPlex 2200 SARS-CoV-2 IgG (Bio-Rad), V-PLEX SARS-CoV-2 Panel 2 IgG (MSD), and Elecsys Anti-SARS-CoV-2 (Roche) commercial assays, as well as for two highly scalable in-house assays (University of Ottawa and Mount Sinai Hospital protocols) to assess their suitability for DBS-based SARS-CoV-2 DBS serosurveillance. These assays were evaluated against identical panels of DBS samples collected from convalescent COVID-19 patients (n = 97) and individuals undergoing routine sexually transmitted and bloodborne infection (STBBI) testing prior to the COVID-19 pandemic (n = 90). Our findings suggest that several assays are suitable for serosurveillance (sensitivity >97% and specificity >98%). In contrast to other reports, we did not observe an improvement in performance using multiple antigen consensus-based rules to establish overall seropositivity. This may be due to our DBS panel which consisted of samples collected from convalescent COVID-19 patients with significant anti-spike, -receptor binding domain (RBD), and -nucleocapsid antibody titers. This study demonstrates that biological specimens collected as DBS coupled with one of several readily available assays are useful for large-scale COVID-19 serosurveillance.
KW - Covid-19
KW - Dried blood spots
KW - Immunoassays
KW - SARS-CoV-2
KW - Serology
KW - Serosurveys
UR - http://www.scopus.com/inward/record.url?scp=85137282237&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.heliyon.2022.e10270
DO - https://doi.org/10.1016/j.heliyon.2022.e10270
M3 - Article
C2 - 36060461
SN - 2405-8440
VL - 8
JO - Heliyon
JF - Heliyon
IS - 9
M1 - e10270
ER -